Answers are grounded in this paper and cite their sources.
Policy review highlights concurrent medical countermeasure trials for Ebola, suggesting that integrated social science is critical to resolve operational and ethical challenges.
The ongoing outbreak of Bundibugyo virus disease (BVD) in the Democratic Republic of the Congo and Uganda has created an urgent need to evaluate medical countermeasures for an Orthoebolavirus for which no licensed vaccine or approved treatment exists.1 Investigational therapeutics are under evaluation, and candidate vaccines, post-exposure prophylaxis, and new diagnostics are being considered or evaluated.2,3 In Bunia, Democratic Republic of the Congo, the PARTNERS adaptive platform trial is evaluating MBP134 and remdesivir for BVD treatment, and the EBO-PEP trial is evaluating oral obeldesivir as post-exposure prophylaxis for high-risk contacts—highlighting overlapping social, ethical, and operational questions across medical-countermeasure research during the same outbreak.
No takes yet. Share an insight, caveat, or question.
Kindombe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: